ArticleJournal of the National Cancer Institute2020
Breast Cancer Mortality After Implementation of Organized Population-Based Breast Cancer Screening in Norway.
Article in Journal of the National Cancer Institute, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Quality-adjusted life years in the presence and absence of organized mammographic screening using data from BreastScreen Norway.International journal of cancer · 2026Article
- Breast cancer mortality among women who have attended BreastScreen Norway, 1996-2023.Breast cancer research : BCR · 2026Article
- A clinical pilot study for personalized risk-based breast cancer screening utilizing a polygenic risk score.PloS one · 2026Article
- Article
- NHS Health Check attendance is associated with reduced multiorgan disease risk: a matched cohort study in the UK Biobank.BMC medicine · 2024Article
- Low-dose aspirin, statins, and metformin and survival in patients with breast cancers: a Norwegian population-based cohort study.Breast cancer research : BCR · 2023Article
- Survival, Incidence, and Mortality Trends in Female Cancers in the Nordic Countries.Obstetrics and gynecology international · 2023Article
- Article
- An analysis of time trends in breast and prostate cancer mortality rates in Lithuania, 1986-2020.BMC public health · 2022Article
- Quality of life among women with symptomatic, screen-detected, and interval breast cancer, and for women without breast cancer: a retrospective cross-sectional study from Norway.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2022Article
- The Role of the 21-Gene Recurrence ScoreCurrent oncology (Toronto, Ont.) · 2022Review
- Comparing cancer and cardiovascular disease trends in 20 middle- or high-income countries 2000-19: A pointer to national trajectories towards achieving Sustainable Development goal target 3.4.Cancer treatment reviews · 2021Review
- Which type of cancer is detected in breast screening programs? Review of the literature with focus on the most frequent histological features.Pathologica · 2021Review
- Response to Zahl.Journal of the National Cancer Institute · 2020Article
- RE: Breast Cancer Mortality After Implementation of Organized Population-Based Screening in Norway.Journal of the National Cancer Institute · 2020Article
- Interpreting Breast Cancer Mortality Trends Related to Introduction of Mammography Screening: A Simulation Study.MDM policy & practiceArticle
Corrections and comments
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe estimated breast cancer (BC) mortality reduction associated with invitations to a nationwide population-based screening program and with changes in treatment. MATERIALS AND
methodsBreastScreen Norway started in 1996 and became nationwide in 2005. It invites women aged 50-69 years to biennial mammographic screening. We retrieved individual-level data for 1 340 333 women from national registries. During 1996-2014 (screening window), women contributed person-years in noninvited and invited periods. We created comparable periods for 1977-1995 (prescreening window) by dividing the follow-up time for each woman into pseudo-noninvited and pseudo-invited periods. We estimated BC mortality for the four periods, using the so-called evaluation model: counting BC deaths in each period for all women diagnosed within the period and counting BC deaths and person-years after screening-age for those diagnosed within screening age. We used a multivariable flexible parametric survival model to estimate hazard ratio (HR) for the effect of invitation and improved treatment.
resultsUsing the regression approach, we found 5818 BC deaths across 16 533 281 person-years. Invitations to screening reduced BC mortality by 20% (HR = 0.80, 95% confidence interval [CI] = 0.70 to 0.91) among women 50 years and older and by 25% (HR = 0.75, 95% CI = 0.65 to 0.86) among screening-aged women. The treatment effect was 23% (HR = 0.77, 95% CI = 0.65 to 0.92) for women 50 years and older and 17% (HR = 0.83, 95% CI = 0.74 to 0.94) for screening-aged women.
conclusionWe observed a similar reduction in BC mortality associated with invitations to screening and improvements in treatment during 1977-2014, among women 50 years and older.
Indexed as
Identifiers
31848605What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.